Drug delivery methods for cancer immunotherapy

Abstract

Despite the fact that numerous immunotherapy-based drugs have been approved by the FDA for the treatment of primary and metastatic tumors, only a small proportion of the population can benefit from them because of primary and acquired resistances. Moreover, the translation of immunotherapy from the bench to the clinical practice is being challenging because of the short half-lives of the involved molecules, the difficulties to accomplish their delivery to the target sites, and some serious adverse effects that are being associated with these approaches. The emergence of drug delivery vehicles in the field of immunotherapy is helping to overcome these difficulties and limitations and this review describes how, providing some illustrative examples. Moreover, this article provides an exhaustive review of the studies that have been published to date on the particular case of hematological cancers. Graphical Abstract (Created with BioRender)

Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System

“…To further improve the targeting capacity of NDDS in tumor cells, there is a need for active targeting nanotechnology, ie, adding targeting ligands to the surface of the LVN-nanocarriers to ensure the NDDS selectively bind to specific receptors on tumor tissues. 79,87 After ligand recognition with a binding site on the tumor tissues, ligand-target interaction causes in-fold of the tumor cell membrane and internalization of NDDS by receptor-mediated endocytosis. 79,88 The common overexpressed specific receptors in HCC with LVN treatment include epidermal growth factor receptor, 89 transferrin…”

Polymersomes as Innovative, Stimuli-Responsive Platforms for Cancer Therapy

“…The functionalization of polymersomes with specific ligands that target receptors overexpressed on tumor cells significantly enhances the uptake of anticancer agents [ 19 , 20 , 21 ]. This targeted approach allows polymersomes to be internalized more efficiently by cancer cells compared to healthy cells, and they exhibit lower toxicity even at higher concentrations [ 20 ].…”